RBDCOV_EU

RBDCOV invites you to a Science Café☕👩🔬 🔴Leave No One Behind! Fostering Inclusion in Clinical Trials Join us for an engaging discussion on the importance of inclusivity in clinical trials, focusing on key groups: immunocompromised individuals and pediatric populations. We’ll explore the challenges and barriers to inclusivity and its impact on public health and treatment effectiveness. Dr. Beatriz Mothe Pujadas, Dr. Pere Soler-Palacín, and Joan Tallada will share insights from their unique perspectives on this essential topic. This will be an open debate, so you'll have the opportunity to participate! 📍 Where: Sala Segarra - Ateneu Barcelonès (Barcelona) and online 📅 When: Monday, November 18, at 17:00 CET 👥 Who: Open to everyone interested in the topic! 🧏♀️💻 How: It’s free. The event will be in Spanish with English translation. Join us in person or online. Register now and don’t miss out! #RBDCOV #InnovationKillsTheVirus #ScienceCafé

Vaccination remains the most effective way to protect from #COVID19. 🔴That’s why at #RBDCOV, we are committed to developing inclusive and representative clinical trials. Read more in the article below! 🔽🔽 https://lnkd.in/dpbK3XNv

Designing clinical trials for children and adolescents requires careful consideration of their unique physiological and developmental needs. Penta Foundation - Child Health Research a key partner, ensures these are prioritised in the #RBDCOV project. 🔴Read our latest specialized article to learn more about this topic: 👉https://lnkd.in/dwfeXv7G #InnovationKillsTheVirus #Inclusive #ClinicalTrials

#RBDCOV in Figures 🔬 HH-3 Trial: Focused on the safety and immune response of a booster dose in adolescents aged 12 --18. 🔵200+ Participants 🔵Positive Preliminary Results #InnovationKillsTheVirus

Our latest article is out! 🥽🥼 Discover how Penta Foundation - Child Health Research promotes health equity through inclusive clinical trials, focusing on the importance of including children to achieve widespread immunity. Read the full article here 🔴👉https://lnkd.in/dwfeXv7G #RBDCOV #InnovationKillsTheVirus

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) is a key partner in the #RBDCOV project, applying their extensive clinical experience to analyse T cell responses using Intracellular Cytokine Assay (ICS) technology.   Discover how this technology works in our latest specialised article! 🔴👉 https://lnkd.in/diyXDXZ3 #InnovatioKillsTheVirus

#RBDCOVTalks is on the air!🔊 Tune in to listen to leading scientists, researchers, medical professionals, and community advocates. Today, Laura Sesma Aguirre 🔴👉https://lnkd.in/djixhdwg, #InnovationKillsTheVirus #RBDCOV

To test how well the #BIMERVAX vaccine works, our partner research laboratories at Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and IrsiCaixa have been assessing both the antibody and immune cell responses during the #RBDCOV trials.   Have a look at our latest specialised article to learn all about it! 🔴👉https://lnkd.in/diyXDXZ3 #RBDCOV #InnovationKillsTheVirus #immunogenicity

Need a podcast for summer? 🌞🎧 Check out our #RBDCOVTalks episode with Laura Sesma Aguirre, from Zabala Innovation Europe, discussing our #RBDCOV project and why teamwork and data sharing are central in health research.   🎙️ https://lnkd.in/dvdPNKiM   #InnovationKillsTheVirus #COVID19 #COVIDVaccine #BIMERVAX

Long #COVID is real and still without a cure 📑 Research continues to find treatments for all demographics, including children and adolescents. RBDCOV_EU is contributing by conducting clinical trials across various age groups.   Read more 🔎 https://lnkd.in/db264zE6 #InnovationKillsTheVirus #RBDCOV